Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Leukemia and Lymphoma

• Publication date

  1992-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428199209053613PMID 1472924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma

  2006cited by this paper
• Beta-2-Microglobulin

  2002cited by this paper
• Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

  1991cited by this paper
• Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma

  1991cited by this paper
• Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.

  1991cited by this paper
• Report of the first workshop on prognostic factors in large-cell lymphomas.

  1991cited by this paper
• Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.

  1991cited by this paper
• Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma.

  1990cited by this paper
• Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

  1990cited by this paper
• Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.

  1990cited by this paper
• Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum copper.

  1990cited by this paper
• m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.

  1990cited by this paper
• Beta 2-microglobulin: its significance and clinical usefulness.

  1990cited by this paper
• Group risk classification of non-Hodgkin's lymphoma.

  1990cited by this paper
• Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen.

  1989cited by this paper
• A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

  1989cited by this paper
• Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.

  1989cited by this paper
• The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.

  1988cited by this paper
• Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.

  1988cited by this paper
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

  1982cited by this paper
• Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

  1982cited by this paper
• An approach to classifying prognostic factors related to survival experience for non‐Hodgkin's lymphoma patients: Based on a series of 982 patients: 1967–1975

  1981cited by this paper
• Prognostic significance of serum lactate dehydrogenase in malignant lymphoma

  1980cited by this paper
• Serum beta 2 microglobulin and its prognostic value in lymphomas.

  1979cited by this paper
• Serum β2 microglobulin and its prognostic value in lymphomas

  1979cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Випадок виявлення патології стравоходу методом динамічної езофагогастросцинтиграфії

  2024cites this paper
• Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET.

  2013cites this paper
• The role of C-reactive protein as a biomarker in dogs with lymphosarcoma

  2013cites this paper
• Prognostication of diffuse large B-cell lymphoma in the rituximab era

  2011cites this paper
• Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.

  2009cites this paper
• Differential diagnosis – chromosomal/molecular changes

  2008cites this paper
• The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

  2008cites this paper
• Rumen-protected Methionine Improves Early-Lactation Performance of Dairy Cattle Under High Ambient Temperatures

  2007cites this paper
• Inhibitory Effects of Bacteriophages on the Growth of Vibrio sp., Pathogens of Shrimp in the Indian Aquaculture Environment

  2007cites this paper
• Choice of endogenous control for gene expression in nonsmall cell lung cancer

  2005cites this paper
• Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

  2005cites this paper
• The Choice of House Keeping Genes in MRD-Quantification of AML1-ETO Positive Acute Myeloid Leukemia

  2004cites this paper
• Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).

  2003cites this paper
• Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies

  2003cites this paper
• Therapy of non-Hodgkin's lymphoma

  2003cites this paper
• Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.

  2001cites this paper
• Tumor Markers in Oncology

  1999cites this paper
• A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

  1999cites this paper
• CLINICAL UTILITY OF BETA 2 MICROGLOBULIN MEASUREMENT.

  1997cites this paper
• Effects of alpha-interferon on serum beta-2-microglobulin.

  1996cites this paper
• Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy.

  1996cites this paper
• Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.

  1995cites this paper
• Acute tumor lysis syndrome and alkali therapy.

  1995cites this paper
• Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.

  1994cites this paper
• The International Index is not useful in the classification of low-grade lymphoma.

  1994cites this paper
• Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.

  1994cites this paper
• OK-432-induced interferon-γ (IFN-γ) production in patients with malignant lymphoma

  1994cites this paper
• [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].

  1994cites this paper
• Investigation of the expression of housekeeping genes in non-Hodgkin's lymphoma.

  1993cites this paper
• Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma.

  1993cites this paper